Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide

Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide

To develop CpG oligodeoxynucleotides (CpG ODNs) based therapy for prevention and treatment of severe acute respiratory syndrome (SARS), we selected a novel CpG ODN (BW001), which displays B-type CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3', and tested...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 118(2006), 2-3 vom: 30. Feb., Seite 180-7
1. Verfasser: Bao, Musheng (VerfasserIn)
Weitere Verfasser: Zhang, Yi, Wan, Min, Dai, Li, Hu, Xiaoping, Wu, Xiuli, Wang, Li, Deng, Ping, Wang, Junzhi, Chen, Jianzhu, Liu, Yongjun, Yu, Yongli, Wang, Liying
Format: Aufsatz
Sprache:English
Veröffentlicht: 2006
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Adjuvants, Immunologic Antiviral Agents CPG-oligonucleotide Oligodeoxyribonucleotides
LEADER 01000naa a22002652 4500
001 NLM159032865
003 DE-627
005 20231223083332.0
007 tu
008 231223s2006 xx ||||| 00| ||eng c
028 5 2 |a pubmed24n0530.xml 
035 |a (DE-627)NLM159032865 
035 |a (NLM)16298165 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Bao, Musheng  |e verfasserin  |4 aut 
245 1 0 |a Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide 
264 1 |c 2006 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 30.03.2006 
500 |a Date Revised 07.12.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a To develop CpG oligodeoxynucleotides (CpG ODNs) based therapy for prevention and treatment of severe acute respiratory syndrome (SARS), we selected a novel CpG ODN (BW001), which displays B-type CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3', and tested for its anti-SARS-CoV activity. We found that the supernatants of human PBMCs stimulated by BW001 significantly protected Vero cells from SARS-CoV infection. BW001 could stimulate human PBMCs and pDCs to secrete high level of IFN-alpha and promote human PBMCs and B cells to proliferate. Furthermore, we demonstrated that BW001 could activate CD19+ B cells and CD56+ NK cells in human PBMCs. In addition, BW001 could enhance NK cytotoxicity and IFN-gamma secretion in human PBMCs. Together, BW001 represents a novel type of CpG ODN and may have potential for the development of treatment and prevention for SARS as well as other viral associated diseases 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a Adjuvants, Immunologic  |2 NLM 
650 7 |a Antiviral Agents  |2 NLM 
650 7 |a CPG-oligonucleotide  |2 NLM 
650 7 |a Oligodeoxyribonucleotides  |2 NLM 
700 1 |a Zhang, Yi  |e verfasserin  |4 aut 
700 1 |a Wan, Min  |e verfasserin  |4 aut 
700 1 |a Dai, Li  |e verfasserin  |4 aut 
700 1 |a Hu, Xiaoping  |e verfasserin  |4 aut 
700 1 |a Wu, Xiuli  |e verfasserin  |4 aut 
700 1 |a Wang, Li  |e verfasserin  |4 aut 
700 1 |a Deng, Ping  |e verfasserin  |4 aut 
700 1 |a Wang, Junzhi  |e verfasserin  |4 aut 
700 1 |a Chen, Jianzhu  |e verfasserin  |4 aut 
700 1 |a Liu, Yongjun  |e verfasserin  |4 aut 
700 1 |a Yu, Yongli  |e verfasserin  |4 aut 
700 1 |a Wang, Liying  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 118(2006), 2-3 vom: 30. Feb., Seite 180-7  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:118  |g year:2006  |g number:2-3  |g day:30  |g month:02  |g pages:180-7 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 118  |j 2006  |e 2-3  |b 30  |c 02  |h 180-7